Table 1. Baseline characteristics of patients in relation to immunoglobulin plasma levels.
| Total IgG | p-value | oxLDL-IgG | p-value | Total IgE | p-value | ||
| Age, mean years (sd) | 67 (9) | r = −0.082 | 0.347 | r = 0.031 | 0.724 | r = 0.097 | 0.265 |
| BMI, mean kg/m2 (sd) | 27 (4) | r = −0.115 | 0.19 | r = 0.001 | 0.995 | r = −0.126 | 0.15 |
| Gender | |||||||
| Male | 96/135 (71%) | 16.8 [11.7–23.5] | 0.694 | 336 [239–499] | 0.074 | 131.1 [57.5–317.4] | 0.169 |
| Female | 39/135 (29%) | 17.2 [12.6–23.1] | 282 [233–358] | 76.7 [31.4–293.4] | |||
| Current smoker | |||||||
| Yes | 55/134 (41%) | 16.6 [10.3–23.3] | 0.635 | 303 [252–481] | 0.427 | 173.4 [65.5–449.8] | 0.032 |
| No | 79/134 (59%) | 17.1 [12.3–23.2] | 306 [219–502] | 91.5 [41.5–203.0] | |||
| Diabetes mellitus | |||||||
| Yes | 25/135 (19%) | 15.4 [12.1–22.9] | 0.63 | 288 [241–391] | 0.554 | 79.8 [41.9–288.5] | 0.329 |
| No | 110/135 (81%) | 17.0 [12.3–23.7] | 320 [238–489] | 125.0 [57.3–312.1] | |||
| Statin Use | |||||||
| Yes | 93/135 (69%) | 17.1 [12.3–22.8] | 0.72 | 288 [224–406] | 0.004 | 97.5 [43.1–276.8] | 0.012 |
| No | 42/135 (31%) | 16.8 [23.3–25.0] | 399 [282–584] | 157.3 [75.2–545.4] | |||
| Hypertension | |||||||
| Yes | 116/135 (86%) | 17.2 [12.5–23.2] | 0.633 | 302 [233–480] | 0.207 | 113.0 [49.1–304.8] | 0.265 |
| No | 19/135 (14%) | 15.0 [10.4–26.0] | 341 [260–537] | 183.3 [68.8–594.0] | |||
| Hypersensitive | |||||||
| Yes | 27/132 (20%) | 17.1 [12.6–22.2] | 0.906 | 305 [233–412] | 0.539 | 148.1 [44.6–449.8] | 0.401 |
| No | 105/132 (80%) | 16.6 [11.6–23.9] | 303 [237–489] | 115.6 [50.5–304.7] | |||
| History VI | |||||||
| Yes | 54/135 (40%) | 18.5 [11.9–23.5] | 0.39 | 297 [216–483] | 0.391 | 86.2 [47.7–274.4] | 0.239 |
| No | 81/135 (60%) | 15.4 [11.9–23.5] | 306 [254–484] | 135.4 [54.2–358.9] | |||
| History MI | |||||||
| Yes | 30/134 (22%) | 19.0 [12.7–22.7] | 0.673 | 321 [222–428] | 0.62 | 85.6 [51.7–282.9] | 0.601 |
| No | 104/134 (78%) | 16.5 [12.2–23.5] | 304 [239–508] | 129.7 [49.1–310.8] | |||
| Clinical presentation | |||||||
| Asymptomatic | 35/135 (26%) | 15.8 [12.3–23.2] | 0.419* | 314 [239–505] | 0.377* | 113.0 [47.0–304.9] | 0.431* |
| Symptomatic | 100/135 (74%) | 18.1 [12.1–24.1] | 293 [224–399] | 144.3 [68.8–356.7] | |||
| Amaurosis fugax | 22/135 (16%) | 16.6 [12.5–24.9] | 296 [240–424] | 120.9 [46.3–327.8] | |||
| TIA | 51/135 (38%) | 16.2 [11.5–23.2] | 300 [223–512] | 106.3 [32.9–281.6] | |||
| Stroke | 27/135 (20%) | 15.4 [12.3–22.7] | 352 [257–515] | 135.4 [66.6–319.9] |
Data are presented as No. (%) and median [IQR] unless otherwise indicated; r = Spearman’s rank correlation coefficient; sd = standard deviation; IQR = interquartile range; BMI = body mass index; TIA = transient ischemic attack; *p-value represents statistical analysis for asymptomatic patients versus symptomatic patients (composed of amaurosis fugax, TIA an stroke).